The financials
Phibro Animal Health Corporation by the numbers
Phibro Animal Health Corporation (PAHC) reported revenue of $384M in Q3 2026 (quarter ended Mar 31, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 33% and net income of $24M (6.3% of revenue). For the full year FY2025, revenue was $1.30B (+27% year on year) and net income $48M. Its largest product in Jun 2026 was Medicated Feed Additives And Others at $208M, 52% of the disclosed total, well ahead of Mineral Nutrition at 19%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $384M | $348M | +10% |
| Gross profit | $126M | $105M | +20% |
| Operating income | $45M | $34M | +33% |
| Net income | $24M | $21M | +15% |
| Diluted EPS | $0.59 | $0.51 | +16% |
| Product | Revenue | Share |
|---|---|---|
| Medicated Feed Additives And Others | $208M | 52% |
| Mineral Nutrition | $77M | 19% |
| Nutritional Specialties | $50M | 13% |
| Vaccines | $40M | 10% |
| Performance Products | $22M | 5.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $396.7M (+3.4%)
Mineral Nutrition grew +20% year on yearMedicated Feed Additives And Others +0.53% year on year
Segment Latestquarter on quarteryear on year
- Medicated Feed Additives And Others$207.6M$207.6MQoQ +0.89%year on year +0.53%+0.89%+0.53%
- Mineral Nutrition$77.0M$77.0MQoQ +4.9%year on year +20%+4.9%+20%
- Nutritional Specialties$49.9M$49.9MQoQ +6.6%year on year +5.3%+6.6%+5.3%
- Vaccines$40.0M$40.0MQoQ +3.7%year on year +3.8%+3.7%+3.8%
- Performance Products$22.2M$22.2MQoQ +17%year on year +0.59%+17%+0.59%
Drug Manufacturers - Specialty & Generic
Ranks #2 of 29 by Smart Score